Levo

Health Canada has granted a Class 2 medical device licence to US-based Otoharmonics’ Levo system, a personalised neuroscience-based sound therapy developed for use in the temporary relief of tinnitus symptoms.

Levo leverages the brain’s natural cognitive abilities to identify and map an individual’s sound print, with the help of custom-fit ear buds and software on Apple’s iPad and iPod touch mobile digital devices.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Tinnitus is often described as ‘ringing in the ears’, which is the result of false signalling in the brain due to inner ear cell damage. It is most commonly caused by exposure to loud noise or hearing loss.

More than 360,000 people in Canada have severe tinnitus and about half of these are so debilitated by the condition that it impairs their quality of life, according to the Tinnitus Association of Canada.

According to the American Tinnitus Association, more than 50 million people in the US experience tinnitus, with two to three million finding the condition debilitating, causing serious problems such as sleep loss, emotional distress and anxiety.

"The Levo system also has the ability to track progress over time and personalise therapy."

Otoharmonics CEO Michael Baker said: "Since announcing FDA 510(k) clearance last month, we’ve received many inquiries from Canadian patients and healthcare providers.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"We’re very pleased to announce that the Levo tinnitus system is now available in Canada."

The company said that with their sound print identified and mapped, patients can listen nightly to a customised therapy using the Levo system while sleeping.

The Levo system can also track progress over time and personalise therapy. In September, the company had secured 510(k) clearance from US Food and Drug Administartion (FDA) for the Levo system.


Image: Patients identify their unique tinnitus sound print using the Levo System. Photo: courtesy of PRNewsFoto/Otoharmonics Corporation.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact